Alvotech's Resubmissions and the Bio-Thera Opening: A Pivotal Quarter
Alvotech's second-quarter 2026 earnings call was a study in controlled optimism. The company emerged from a year of FDA-driven disruptions with its manufacturing remediation complete, four U.S. biologics license applications resubmitted, and a competitor's stumble potentially opening the door for an even stronger golimumab franchise. The tone was set by founder Róbert Wessman, who framed the quarter as a turning point.
A Regulatory Turning Point
The most tangible progress came from the FDA. The agency closed its May surveillance inspection of Alvotech's Reykjavik facility with a Voluntary Action Indicated (VAI) classification, and the company resubmitted BLAs for its proposed biosimilars to Simponi, EYLEA, and Prolia/Xgeva in June. Joseph McClellan, COO, told investors that the FDA acknowledged the resubmissions as complete responses, with goal dates aligned to the standard six-month clock. “In July, the agency formally closed that inspection with a voluntary action indicated classification.” — Joseph McClellan, Senior Executive or Head of Regulatory/Development (inferred from regulatory updates) · 2026-08-20 The VAI outcome is a clear signal that the agency is satisfied with the remediation efforts, which included more than 180 corrective actions. That is a far cry from the tone a year ago, when Joseph was committing to those actions: “We have committed to the FDA to complete more than 180 different changes to address all of their observations plus more so that we will not be in the situation again.” — Joseph McClellan, Chief Operating Officer · 2025-11-13 The resubmissions position Alvotech for potential approvals in the fourth quarter, potentially the first biosimilar for golimumab in the U.S.
The Bio-Thera Opening
The call's most interesting company-specific development was the mention of Bio-Thera, a competitor whose golimumab biosimilar has faced regulatory challenges. Lisa Graver, now CEO, noted that Alvotech's European partner, Advanz, is "doing everything it can to take advantage of the fact that we are truly first in the market." “Christopher, thanks for the question. So on Bio-Thera, certainly, we are looking and our partner in Europe, Advance is doing everything it can to take advantage of the fact that we are truly first in the market.” — Lisa Graver, Senior Executive, likely Head of Commercial or Strategy (inferred from commercial and strategic discussions) · 2026-08-20 The company has been building supply in anticipation, and with a strong share position in Europe, the disruption could accelerate Alvotech's already prominent role. In the U.S., Alvotech expects approval in Q4 and is actively clearing IP litigation, confident of being within the first wave. The Bio-Thera news is a tailwind that analysts did not fully price in, and it highlights the proposed biosimilar opportunity.
Financing and the Path to Cash Flow
The company's capital position was significantly strengthened during the quarter. An equity offering raised approximately $165 million in gross proceeds, and an additional term loan facility of up to $75 million was secured. Linda Jonsdottir, CFO, reaffirmed guidance for 2026: revenues of $650-700 million and adjusted EBITDA of $180-220 million, positioning the fourth quarter as the strongest of the year. “We target revenues in the range of $650 million to $700 million, representing continued double-digit annual growth from last year.” — Linda Jonsdottir, CFO or Head of Finance (inferred from financials discussion) · 2026-08-20 The equity financing also brought in 20 new healthcare-focused investors, broadening the shareholder base. The capital will fund the biosimilar pipeline and prepare for multiple launches.
Beyond the Immediate Approvals
Alvotech is also positioning for its next wave of biosimilars, including candidates for ENTYVIO and KEYTRUDA. The improvement program has laid the groundwork for a more reliable manufacturing platform, and the company is exploring direct U.S. commercialization for select pipeline products. Lisa said, "We see opportunities for Alvotech to participate more directly in the U.S. market," a strategic shift from its pure B2B model. The pipeline is one of the broadest in the industry, with more than 30 candidates in development. This builds on the earlier commitment to diversify manufacturing, as Lisa outlined in a prior call: “It is an ability for us to diversify our capacity across markets, certainly having a presence in the United States as well does give us the advantage being one of our large markets.” — Lisa Graver, Chief Commercial Officer · 2026-05-07 The Fujifilm partnership is on track to deliver product by the second half of 2027, further de-risking the supply story.
We are optimistic about our first-mover position with our ENTYVIO biosimilar program. We were the first to submit a BLA in the U.S., and we have also submitted a marketing application in Europe, addressing a global market of $7 billion.
The quarter represents a clean break from the past year of uncertainty. With resubmissions in hand, a supportive capital structure, and a competitor setback, Alvotech's execution risk has diminished meaningfully. The focus now shifts to the fourth quarter, where approvals and milestone revenues should crystallize the company's turnaround.